ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

ClinicalTrials.gov ID: NCT01909453

Public ClinicalTrials.gov record NCT01909453. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Study identification

NCT ID
NCT01909453
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
921 participants

Conditions and interventions

Conditions

Interventions

  • LGX818 Drug
  • MEK162 Drug
  • vemurafenib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 11, 2013
Primary completion
Nov 8, 2016
Completion
Sep 2, 2024
Last update posted
Feb 26, 2026

2013 – 2024

United States locations

U.S. sites
50
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
Retinal Consultants of Alabama P.C. Birmingham Alabama 35233
UAB Callahan Eye Hospital Birmingham Alabama 35233
UAB Comprehensive Cancer Center Birmingham Alabama 35233
UAB The Kirklin Clinic Birmingham Alabama 35233
University of Alabama at Birmingham Birmingham Alabama 35243
University of Alabama at Birmingham Birmingham Alabama 35294
Arizona Oncology Associates Tucson Arizona 85710
Highlands Oncology Group Fayetteville Arkansas 72703
Highlands Oncology Group Rogers Arkansas 72758
Highlands Oncology Group - Fayetteville Springdale Arkansas 72762
UC Irvine Medical Center Orange California 92868
Rocky Mountain Cancer Centers (Williams) - USOR Aurora Colorado 80012
Rocky Mountain Cancer Centers Boulder Colorado 80303
Rocky Mountain Cancer Centers Colorado Springs Colorado 80907
Rocky Mountain Cancer Centers (Williams) - USOR Denver Colorado 80218
Rocky Mountain Cancer Centers Lakewood Colorado 80228
Specialty Eye Care Parker Colorado 80134
Rocky Mountain Cancer Centers Pueblo Colorado 81008
University Cancer Institute Boynton Beach Florida 33426
University of Miami Miami Florida 33136
Eye & Ear Infirmary- Opthalmology Chicago Illinois 60612
University of Illinois at Chicago Chicago Illinois 60612
University of Illinois Hospital and Health Sciences System - Investigational Drug Service Chicago Illinois 60612
University of Illinois Hospital and Health Sciences System Chicago Illinois 60612
University of Illinois Medical Center Chicago Illinois 60612
Oncology Specialists, SC Niles Illinois 60714
Goshen Center For Cancer Care Goshen Indiana 46526
Lack's Cancer Center at Mercy Health Saint Mary's Grand Rapids Michigan 49503
Mercy Health Hauenstein Neuroscience Center Neuro-Ophthalmology (Clinic) Grand Rapids Michigan 49503
Retina Specialists of Michigan Grand Rapids Michigan 49525
Hattiesburg Clinic Oncology Hem Hattiesburg Mississippi 39401
Jackson Oncology Associates - St. Dominic Hospital Jackson Mississippi 39202
Nebraska Methodist Hospital Omaha Nebraska 68114
Hackensack University Medical Center Hackensack New Jersey 07601
Investigational Drug Service, Department of Pharmacy (Investigational Product) Rochester New York 14642
University of Rochester Medical Center - PPDS Rochester New York 14642
Tulsa Cancer Institute PLLC Tulsa Oklahoma 74146
University of Pittsburgh Cancer Institute Pittsburgh Pennsylvania 15232
Sanford Cancer Center Oncology Clinic & Pharmacy Sioux Falls South Dakota 57104
University of Tennessee Medical Center Cancer Institute Knoxville Tennessee 37920
Dr. Dennis B. Kay (Ophthalmologist) Dallas Texas 75231
Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas Texas 75246
UT Southwestern Medical Center at Dallas Dallas Texas 75390
University of Vermont Medical Center Burlington Vermont 05401
Virginia Cancer Specialists, PC Alexandria Virginia 22304
Virginia Cancer Specialists Arlington Virginia 22205
Virginia Cancer Specialists (Leesburg) - USOR Fairfax Virginia 22031
Northern Virginia Ophthalmology Associates Falls Church Virginia 22044
Virginia Cancer Specialists, PC Gainesville Virginia 20155
Wenatchee Valley Hospital & Clinics Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 232 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01909453, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01909453 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →